CLOs on the Move

US Ecology

www.usecology.com

 
US Ecology, Inc. is a leading North American provider of environmental services to commercial and government entities. The Company addresses the complex waste management needs of its customers, offering treatment, disposal and recycling of hazardous and radioactive waste, as well as a wide range of complementary field and industrial services. US Ecology's focus on safety, environmental compliance, and customer service, enables us to effectively meet the needs of our customers and to build long-lasting relationships. Headquartered in Boise, Idaho, with operations in the United States, Canada and Mexico, the Company has been protecting the environment since 1952. To protect and improve ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $500M-1 Billion
  • www.usecology.com
  • 251 E Front St. Suite 400
    Boise, ID USA 83702
  • Phone: 800.590.5220

Executives

Name Title Contact Details
Wayne Ipsen
 Vice President, General Counsel and Secretary Profile
Brian Lindman
 Vice President, Environmental Compliance Profile
Andy Marshall
 Executive Vice President, Regulatory Compliance and Safety Profile

Similar Companies

Shionogi USA

Shionogi USA, Inc. is a Florham Park, NJ-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Luzsana Biotechnology

Luzsana Biotechnology™ is a new kind of biotech company with a mission to make innovative medicines available, accessible, and affordable to anyone, anywhere.

BlueSphere Bio

Rapid, Personalized T-cell Therapies for Cancer on BlueSphere Bio…

Drug Development Resources

Drug Development Resources is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immunicom

Immunicom, Inc. is a privately held medical technology company that develops subtractive therapies for cancer, autoimmune disorders, and inflammatory and renal diseases. Immunicom`s blood-filtering Immunopheresis technology has the potential to effectively treat a wide variety of cancer types and other terminal diseases with a safer side-effect profile than conventional treatments. Immunicom`s lead product, the LW-02 column, previously received FDA Breakthrough Device designation in 2018 for stage IV metastatic cancer, and European regulatory clearance (CE Mark certification) in 2021 for use in adults with advanced, refractory, triple negative breast cancer. Immunopheresis is being evaluated in several global oncology trials for multiple cancers. Immunicom is headquartered in San Diego, CA with operations in Houston, TX, Philadelphia, PA, Krakow, Poland, and Istanbul, Turkey.